XylR mutant for improved xylose utilization or improved co-utilization of glucose and xylose preliminary
The disclosure relates to mutant gene(s) that confer upon microorganisms that express them an improved capacity to utilize xylose and improved capacity to co-utilize glucose and xylose thereby resulting in improved growth of the microorganism. Further encompassed are methods of producing fatty acids and fatty acid derivatives from cellulosic biomass, xylose, and/or a glucose/xylose mix by employing the host cells expressing the engineered XylR variants and compositions of biologically produced fatty acids and fatty acid derivatives.
1. An engineered XylR protein variant, comprising at least 80% sequence identity to SEQ ID NO: 1 and comprising at least one mutation corresponding to one or more of V83C, H88G, L89K, L112R, N120C, Y141R, Q145R, L146R, V147M, E150W, E150G, V155E, A247V, R270E, R280V, A286M, A286F, Q289V, D305M, D305G, Q306K, I313L, M333R, E337H, L351T, S364W, L365T, L365V, F372W, or E382K, with reference to SEQ ID NO: 1.
2. The engineered XylR protein variant of claim 1 , wherein the engineered XylR protein variant has at least 85%, 90%, or 95% sequence identity to SEQ ID NO: 1.
3. The engineered XylR protein variant of claim 1 , comprising at least one mutation corresponding to L112R, Y141R, Q145R, L146R, A247V, A286M, A286F, Q289V, R295C, E337H, S364W, or L365V, or a combination thereof.
4. The engineered XylR protein variant of claim 1 , further comprising a mutation at an amino acid position corresponding to position 121 or 363 or a combination thereof.
5. The engineered XylR protein variant of claim 4 , wherein the mutation at position 121 or 363 is R121C, R121S, R121T, R121G, R121H, R121V, R121M, R121Y, R121I, R121A, R121L, R121P, R121F, R121W, or P363S.
6. The engineered XylR protein variant of claim 1 , wherein expression of the engineered XylR protein variant in a recombinant host cell confers improved growth on the recombinant host cell in comparison to the growth of a host cell expressing SEQ ID NO: 1, when the cells are cultured in the presence of xylose.
7. The engineered XylR protein variant of claim 1 , wherein heterologous expression of a polynucleotide encoding the engineered XylR protein variant in a recombinant host cell confers improved xylose utilization, in comparison to a host cell expressing SEQ ID NO:1, when the cells are cultured in the presence of xylose.
8. The engineered XylR protein variant of claim 1 , comprising at least one mutation corresponding to one or more of L112R, Q145R, L146R, A247V, A286M, E337H, or L365V.
9. A recombinant host cell that expresses the engineered XylR protein variant of claim 1 , wherein the engineered XylR protein is encoded by a heterologous nucleic acid.
10. The recombinant host cell of claim 9 , wherein:
expression of the engineered XylR protein variant in the recombinant host cell confers improved xylose utilization, in comparison to a host cell expressing SEQ ID NO:1, when the cells are cultured in the presence of xylose; and/or
expression of the engineered XylR protein variant in the recombinant host cell confers improved growth on the recombinant host cell in comparison to the growth of a host cell expressing SEQ ID NO: 1, when the cells are grown in the in the presence of xylose.
11. The recombinant host cell of claim 9 , wherein the recombinant host cell is a species of Escherichia, Bacillus, Lactobacillus, Pseudomonas, Aspergillus , or Marinobacter.
12. The recombinant host cell of claim 9 , wherein the recombinant host cell expresses at least one heterologous fatty acid derivative biosynthetic enzyme, and the recombinant host cell produces one or more fatty acid derivatives.
13. The recombinant host cell of claim 12 , wherein the recombinant host cell produces an increased amount of fatty acid species (FAS) as compared to an otherwise isogenic host cell that expresses SEQ ID NO:1, when cultured in the presence of xylose.
14. A method for preparing a fatty acid derivative, the method comprising culturing, in a culture medium comprising xylose, the recombinant host cell of claim 12 .
15. The recombinant host cell of claim 9 , wherein the engineered XylR protein variant comprises at least one mutation corresponding to one or more of L112R, Q145R, L146R, A247V, A286M, E337H, L365V, and E382K.
16. The recombinant host cell of claim 9 , wherein the engineered XylR protein variant further comprises a mutation at an amino acid position corresponding to position 121 or 363 of SEQ ID NO:1.
17. A method for increasing xylose utilization in a recombinant host cell, the method comprising:
culturing, in a culture medium comprising xylose, the recombinant host cell of claim 9 ,
wherein expression of the engineered XylR protein variant confers improved xylose utilization of the recombinant host cell in comparison to the xylose utilization of a host cell expressing SEQ ID NO: 1, when the cells are cultured in the presence of xylose.
18. The method of claim 17 , wherein:
the recombinant host cell further comprises at least one heterologous fatty acid derivative biosynthetic enzyme; and
the recombinant host cell produces one or more fatty acid derivatives.
19. The method of claim 18 , wherein:
the heterologous fatty acid derivative biosynthetic enzyme is one or more of an ester synthase, an acyl-ACP reductase (AAR), a thioesterase, an alcohol dehydrogenase, an ω-hydroxylase, an aldehyde reductase, an acyl-CoA synthetase, an acyl-CoA reductase (ACR), a carboxylic acid reductase (CAR), an aminotransferase, an amine dehydrogenase, an alcohol O-acyltransferase, a fatty alcohol-forming acyl-CoA reductase (FAR), a fatty acid decarboxylase, a decarbonylase, an oxidative deformylase, a fatty alcohol O-acetyl transferase, OleA having activity for production of ketones, or OleABCD having activity for production of internal olefins; and
the fatty acid derivative is a fatty acid, a fatty ester, a fatty acid methyl ester (FAME), a fatty acid ethyl ester (FAEE), a fatty alcohol acetate ester (FACE), a fatty alcohol, a fatty aldehyde, a hydrocarbon, a fatty amine, a fatty amide, an alkane, an alkene, a terminal olefin, an internal olefin, a fatty ketone, a fatty diacid, a fatty diol, a 1,3-fatty diol, an omega-hydroxy fatty acid, an omega-hydroxy diol, an omega-hydroxy FAME, or an omega-hydroxy FAEE, or a combination thereof.
20. The method of claim 17 , wherein the engineered XylR protein variant comprises at least one mutation corresponding to one or more of L112R, Q145R, L146R, A247V, A286M, E337H, L365V, and E382K.